Document is current
Any future updates will be listed below
-
Authors
Ćavar Pavić, Jakica https://orcid.org/0009-0009-7573-6921
Cullinan, Noelle https://orcid.org/0000-0002-4840-5010
Jongmans, Marjolijn
Bourdeaut, Franck https://orcid.org/0000-0001-9489-6781
Wadt, Karin
LoNigro, Luca
Davies, Mark
Michaeli, Orli
Strang-Karlsson, Sonja
de Putter, Robin https://orcid.org/0000-0001-9410-8941
Sepulchre, Edith
Cazzaniga, Giovanni
Furtwängler, Rhoikos https://orcid.org/0000-0002-1967-8343
Zweier, Christiane https://orcid.org/0000-0001-8002-2020
Rössler, Jochen
Waespe, Nicolas https://orcid.org/0000-0002-2271-8959
- License Information
-
More Information
Article History
Received: 30 September 2025
Revised: 5 January 2026
Accepted: 4 February 2026
First Online: 2 March 2026
Competing interests
: NW reports a relationship with Swedish Orphan Biovitrum AB that includes advisory board membership, consulting, and travel reimbursement, a relationship with NovoNordisk that includes advisory board and travel reimbursement, and a relationship with Novartis that includes advisory board membership. None of these relationships are in association with the current study. LL reports an advisory board role in AMGEN, JAZZ PHARMA, CLINIGEN. JR became an employee of Novartis Pharma Basel after the setup and start of this research project.
: The ethics committee of the canton of Bern, Switzerland, waived an ethics evaluation (Req-2022-00455). All participants consented to the project prior to conducting the surveys.
